Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
144.88
+1.15 (0.80%)
Oct 12, 2026, 4:00 PM EDT - Market closed
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Protagonist Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $178.21. The average 1-year stock price forecast is 23.01% higher than the current stock price, while the lowest is $149 (+2.84%) and the highest is $225 (+55.30%).
Price Target: $178.21 (+23.01%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 10 | 10 | 11 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Reiterates $150 → $190 | Buy | Reiterates | $150 → $190 | +31.14% | Oct 12, 2026 |
| UBS No rating | UBS | Buy Initiates $184 | Buy | Initiates | $184 | +27.00% | Oct 12, 2026 |
| Citi | Citi | Buy Maintains $175 → $182 | Buy | Maintains | $175 → $182 | +25.62% | Sep 10, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $186 | Buy | Maintains | $186 | +28.38% | Sep 1, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $149 | Buy | Reiterates | $149 | +2.84% | Sep 1, 2026 |
Financial Forecast
Revenue This Year
541.64M
from 46.02M
Increased by 1,077.07%
Revenue Next Year
211.30M
from 541.64M
Decreased by -60.99%
EPS This Year
4.66
from -2.05
EPS Next Year
-0.14
from 4.66
EPS and Forward PE are based on non-GAAP adjusted numbers.